This application of IGF-1 receptor antagonists complements Insmed and UCSF’s ongoing clinical studies with INSM-18, a small molecule IGF-1 tyrosine kinase inhibitor in a phase I clinical study in patients with relapsed prostate cancer.
Researchers at University of California, San Francisco (UCSF), a National Cancer Institute designated Comprehensive Cancer Center, will lead the investigative efforts with IGF-1 receptor antagonists to identify the compound with an ideal risk/benefit ratio to enter clinical trials.
“We are very excited to expand the company pipeline with this patented methodology,” commented Insmed’s CEO Dr Geoffrey Allan. “This agreement with UCSF further broadens our pipeline of promising drug candidates in the prostate cancer field, and reinforces Insmed as a leader in IGF biology and growth factor signaling.”